BIO Early-Stage Resources Hub
BIO is re-launching a streamlined version of our FDA communications survey to gauge the effectiveness of FDA-sponsor interactions during drug development. This brief survey asks about topics such as communications channels, special designations, and clinical holds.click here to go to the survey. After you access the survey, you will receive a personalized link via email. If you don’t see the email, please check your spam folder. Once you receive the link, you can begin the survey, which takes about 5 minutes to complete.The survey is pivotal for BIO’s ongoing efforts to ensure the FDA review process is working as well as it can. In the past, a similar survey has been critical in our continuous efforts to work with FDA on best practices and to reauthorize PDUFA. The results will be incorporated into BIO’s advocacy agenda to ensure a science-driven, innovative, well-resourced FDA. To participate, simply
Participating companies will receive exclusive access to survey data during a webinar in 2024. All data and feedback will be email@example.com. Thank you in advance for your participation in this important effort!If you have questions about the survey you may reach out to
BIO Office Hours is a resource for BIO members to meet one-on-one with subject matter experts on business services. Every month, BIO invites an expert to provide an overview of business critical topics followed by the opportunity for BIO Members to meet with the expert, ask questions, and learn more.
We hosted several key topics during BIO Office Hours this year, like R&D tax credits, grant writing, and regulatory inspections. If you missed one, BIO members can now schedule an appointment with a subject matter expert on a previously featured topic. Fill out this form to select your interested topic and availability.